Tadeusz (‘Ted’) Molinski, PhD Natural Product Drug Design Overview Therapeutic Areas of Interest • Natural Products – sources of drug leads • Isolation-structure elucidation of marine natural products (MNPs) • Organic synthesis & Structure-Activity Relationships (SAR) • Medicinal Chemistry • Antifungals to azole-resistant yeast (e.g. Candida spp. emergent pathogens (e.g. Crypto. grubii, & C. gatti) • Cancer – CLL, solid tumors, c-kit, wnt develop. pathways, HDAC inhibitors S Crypto. grubii : MIC 50 0.85 µM
3
Embed
Tadeusz (‘Ted’) Molinski, PhD Natural Product Drug Design Overview Therapeutic Areas of Interest Natural Products – sources of drug leads Isolation-structure.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Tadeusz (‘Ted’) Molinski, PhDNatural Product Drug Design
Overview
Therapeutic Areas of Interest
• Natural Products – sources of drug leads• Isolation-structure elucidation of marine natural products (MNPs)• Organic synthesis & Structure-Activity Relationships (SAR)• Medicinal Chemistry
• Antifungals to azole-resistant yeast (e.g. Candida spp. emergent pathogens (e.g. Crypto. grubii, & C. gatti)• Cancer – CLL, solid tumors, c-kit, wnt develop. pathways, HDAC inhibitors• Ca2+ ion channels: ‘channelopathies’
S
Crypto. grubii : MIC50 0.85 µM
Core Expertise
Natural Products - Discovery• Collection-archiving of marine invertebrates• Isolation-purification, structure elucidation (SE) of rare MNPs– Nuclear Magnetic Resonance (NMR)– Mass spectrometry (MS), FTIR, circular dichroism (CD)– Integrated techniques: synthesis & spectr. methods• Chemical biology – mechanism/target of action.• Method development and application for SE (NMR, CD)
Organic Synthesis• Medicinal Chemistry – ‘short-order cook’• Total Synthesis of complex MNPs – ’grand banquet’• SAR – refinement of lead compounds
Proposed Collaborations with SSPPS Faculty
MNP – ligand binding targets
• Chemical biology of natural products – ‘pull down’ of cognate receptor/enzymes – proteomics: identification of high-affinity protein targets – target validation
MNP – screening and post-lead • Eukaryotic pathogens – fungal infectious disease (histoplasmosis, coccidiomycoses) – PK, PD, ADME – in vivo animal models, trials
CLL: IC50 66 nM*
* Collaboration with Drs. Januario Castro & Michael Choi, MCC